Conclusion
Owing to the straightforward synthesis and chemical modification, high target specificity, low toxicity, and broad range of targets, peptides have become a viable option for treating various diseases. This review provides an overview of the studies that employ organoids to assess the effects of peptide candidates, exploring the utility and challenges of high-throughput screening of peptide using organoids in light of the experiences from the organoid-based small molecule screens that have been extensively examined in recent years. Despite the limitations and difficulties in developing an organoid-based peptide high-throughput platform, various techniques can be employed to overcome these issues, including the advancement of organoid technology. Consequently, organoids will be a captivating and novel preclinical model for discovering peptide drugs in the future.